Ipca Laboratories has reported results for third quarter ended December 31, 2013.
The company has reported 58.28% rise in its net profit at Rs 139.12 crore for the quarter as compared to Rs 87.89 crore for the same quarter in the previous year. Total income from operations of the company has increased by 18.91% at Rs 838.37crore for quarter under review as compared to Rs 704.99 crore for the quarter ended December 31, 2012.
IPCA Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
The company has reported 58.28% rise in its net profit at Rs 139.12 crore for the quarter as compared to Rs 87.89 crore for the same quarter in the previous year. Total income from operations of the company has increased by 18.91% at Rs 838.37crore for quarter under review as compared to Rs 704.99 crore for the quarter ended December 31, 2012.
IPCA Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
No comments:
Post a Comment